By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in Nanoparticles. According to news reporting out of Mumbai, India, by NewsRx editors, research stated, "The purpose of the research was to prepare and evaluate a topical nanolipidgel (NLH) of terbinafine hydrochloride (TRB), an antimycotic agent, for enhanced skin deposition and improved antifungal activity. Topical solid lipid nanoparticles (SLN) based nanolipidgel was formulated and evaluated."
Our news journalists obtained a quote from the research from the Institute of Chemical Technology, "TRB-loaded SLNs were formulated by high-pressure homogenization technique. The stable TRB SLN dispersion was incorporated into a gel using 1% Carbopol 980 NF. Rheological evaluation and texture analysis of the TRB NLH was carried out. Skin permeation, skin deposition, antifungal activity, and occlusivity studies of the nanolipidgel formulation were carried out. The safety of the TRB NLH gel was evaluated using acute skin irritation test on New Zealand White rabbits. The SLN dispersion containing 10% of glyceryl monostearate, 3% of Tween 80, and 1% Plurol Oleique was the most stable. The optimized TRB SLN had a particle size and zeta potential value of 148.6±0.305 nm and -20.4±1.2 mV, respectively. TRB NLH had excellent rheological and texture properties to facilitate its topical application. TRB NLH showed increased skin deposition of the drug over plain (3-fold) and marketed TRB formulation (2-fold). TRB NLH had significantly enhanced antifungal activity against Candida albicans. TRB NLH showed efficient occlusivity and was non-irritant to the rabbit skin with no signs of erythema or edema."
According to the news editors, the research concluded: "Solid lipid nanoparticles-based topical nanolipidgel of terbinafine can be an efficient, industrially scalable, and cost-effective alternative to the existing conventional formulations."
For more information on this research see: Nanolipidgel for enhanced skin deposition and improved antifungal activity. Aaps Pharmscitech [electronic Resource], 2013;14(1):222-33. Aaps Pharmscitech [electronic Resource] can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA (see also Nanoparticles).
Our news journalists report that additional information may be obtained by contacting P. Wavikar, Center for Novel Drug Delivery Systems, Dept. of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga (E), 400019, Mumbai, India.
Publisher contact information for the journal Aaps Pharmscitech [electronic Resource] is: Springer, 233 Spring Street, New York, NY 10013, USA.
Keywords for this news article include: Asia, India, Mumbai, Nanotechnology, Emerging Technologies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC